<DOC>
	<DOCNO>NCT00193024</DOCNO>
	<brief_summary>The epirubicin/docetaxel combination one active best tolerated taxane/anthracycline combination . In phase II trial , evaluate feasibility , safety effectiveness docetaxel/epirubicin combination , administer first-line treatment metastatic breast cancer .</brief_summary>
	<brief_title>Epirubicin Docetaxel Treatment Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Docetaxel + Epirubicin Both drug repeat 21-day interval</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic breast cancer confirm biopsy . Received previous chemotherapy metastatic breast cancer . Prior hormonal therapy acceptable . Measurable evaluable disease . Able perform activity daily live without considerable assistance Adequate bone marrow , liver kidney function Must able understand nature study give write informed consent . You participate study follow apply : Age &lt; 18 year . Cardiac ejection fraction &lt; 45 % . Women pregnant lactating . Patients meningeal metastasis ineligible . Moderate peripheral neuropathy History hypersensitivity reaction Taxotere Males metastatic breast cancer Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>